- Home
- RRX vs EXEL Comparison
RRX vs EXEL Comparison
Compare RRX & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRX
- EXEL
- Stock Information
- Founded
- RRX 1955
- EXEL 1994
- Country
- RRX United States
- EXEL United States
- Employees
- RRX N/A
- EXEL N/A
- Industry
- RRX
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RRX
- EXEL Health Care
- Exchange
- RRX Nasdaq
- EXEL Nasdaq
- Market Cap
- RRX 8.9B
- EXEL 9.8B
- IPO Year
- RRX 1987
- EXEL 2000
- Fundamental
- Price
- RRX $133.50
- EXEL $43.04
- Analyst Decision
- RRX Strong Buy
- EXEL Buy
- Analyst Count
- RRX 9
- EXEL 18
- Target Price
- RRX $171.25
- EXEL $38.76
- AVG Volume (30 Days)
- RRX 876.1K
- EXEL 3.9M
- Earning Date
- RRX 05-05-2025
- EXEL 05-13-2025
- Dividend Yield
- RRX 1.05%
- EXEL N/A
- EPS Growth
- RRX N/A
- EXEL 237.58
- EPS
- RRX 3.50
- EXEL 2.20
- Revenue
- RRX $5,904,200,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- RRX N/A
- EXEL $10.39
- Revenue Next Year
- RRX $3.98
- EXEL $10.74
- P/E Ratio
- RRX $38.12
- EXEL $19.53
- Revenue Growth
- RRX N/A
- EXEL 24.49
- 52 Week Low
- RRX $90.56
- EXEL $20.40
- 52 Week High
- RRX $185.28
- EXEL $48.85
- Technical
- Relative Strength Index (RSI)
- RRX 55.27
- EXEL 59.93
- Support Level
- RRX $130.26
- EXEL $42.21
- Resistance Level
- RRX $140.20
- EXEL $43.75
- Average True Range (ATR)
- RRX 3.67
- EXEL 1.60
- MACD
- RRX -1.04
- EXEL -0.09
- Stochastic Oscillator
- RRX 18.26
- EXEL 53.96
About RRX Regal Rexnord Corporation
Regal Rexnord Corp is in the engineering and manufacturing of industrial powertrain solutions, power transmission components, electric motors, electronic controls, air-moving products, and specialty electrical components and systems, serving customers around the world. The four operating segments include Commercial Systems, Industrial Systems, Climate Solutions, and Motion Control Solutions.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.